Vimarsana
Biggest News Aggregation in the World

Page 12 - Adjuvant News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Adjuvant. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Adjuvant Today - Breaking & Trending Today

Eli Lilly: FDA Approves Verzenio In Adjuvant Treatment Of HR+ HER2- Early Breast Cancer - Vimarsana News

Eli Lilly: FDA Approves Verzenio In Adjuvant Treatment Of HR+ HER2- Early Breast Cancer

INDIANAPOLIS (dpa-AFX) - Eli Lilly and Company (LLY) said the FDA has approved its Verzenio, in combination with endocrine therapy, for the adjuvant treatment of adult patients with hormone receptor-positive

New vaccine protects the previously infected - Vimarsana News

New vaccine protects the previously infected

Chinese biotechnology company Clover Biopharmaceuticals said on Wednesday that a large trial shows its two-dose COVID-19 vaccine is 79 percent effective against the fast-spreading Delta variant, which was first detected in India.

Merck: FDA Grants Priority Review To SBLA For KEYTRUDA As Adjuvant Immunotherapy In RCC - Vimarsana News

Merck: FDA Grants Priority Review To SBLA For KEYTRUDA As Adjuvant Immunotherapy In RCC

KENILWORTH (NJ) (dpa-AFX) - Merck (MRK) said the FDA has accepted and granted priority review for a new supplemental Biologics License Application for KEYTRUDA as adjuvant therapy in certain patients

More Support for Gene Assay to Guide Breast Cancer Treatment - Vimarsana News

More Support for Gene Assay to Guide Breast Cancer Treatment

email article Patients with ultralow-risk breast cancer according to genomic assessment had excellent long-term outcomes regardless of clinical risk or whether they received adjuvant therapy, a new analysis of a randomized trial showed. The 8-year breast cancer-specific survival (BCSS) was 99.2% among patients classified as clinically high-risk but ultralow-risk by the MammaPrint 70-gene assay. Patients with an ultralow-risk genomic assessment and low clinical risk had an 8-year BCSS of 99.7%. Freedom from distant metastasis at 8 years was 97.6% in patients who were clinically and genom...

Adding Chemo to Standard Care No Help for Cervical Cancer - Vimarsana News

Adding Chemo to Standard Care No Help for Cervical Cancer

Similar OS, PFS, and patterns of recurrence, with more toxicity